- Pemetrexed2009 | Publication without faculty affiliation
- The role of pemetrexed in treating lung cancer2010 | Faculty of Medicine in Hradec Králové
- Therapy of metastatic non-squamous lung cancer with bevacizumab plus pemetrexed2016 | Faculty of Medicine in Pilsen
- Efficiency and safety of pemetrexed and cisplatin therapy in the adenocarcinoma and large cell cancer types of advanced non-small cell lung cancer (NSCLC) +12012 | Publication without faculty affiliation
- Commenting on the study: efficacy and safety of maintenance treatment with pemetrexed in patients with advanced NSCLC nonskvamózním after induction therapy with pemetrexed plus cisplatin - comparison studies JMBD and PARAMOUNT2014 | Publication without faculty affiliation
- Continuation maintenance therapy with pemetrexed in patients with non-small-cell lung cancer in the Czech Republic2016 | First Faculty of Medicine
- ROS1 - another potencional target of our patients2014 | Faculty of Medicine in Pilsen
- Follow-up of expensive pneumo-oncological treatment of advanced non-small cell lung cancer in the I. line of the TULUNG register in the Czech Republic2013 | First Faculty of Medicine, Faculty of Medicine in Pilsen, Central Library of Charles University
- Clinical registry TULUNG2012 | Faculty of Medicine in Pilsen, Third Faculty of Medicine
- Prognostic role of serum C-reactive protein in patients with advanced-stage NSCLC treated with pemetrexed2017 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Pemetrexed Versus Erlotinib in the Second-line Treatment of Patients with Advanced-stage Non-squamous NSCLC Harboring Wild-type EGFR Gene2016 | Faculty of Medicine in Pilsen, Faculty of Science
- Prognostic Significance of Serum Tumor Markers in Patients with Advanced-stage NSCLC Treated with Pemetrexed-based Chemotherapy2016 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Sequential Treatment of Advanced-stage Lung Adenocarcinoma Harboring Wild-type EGFR Gene: Second-line Pemetrexed Followed by Third-line Erlotinib versus the Reverse Sequence2013 | Faculty of Medicine in Pilsen
- Development of method and stability study of pharmaceutical formulation / 2016Publication without faculty affiliation
- A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer2008 | Third Faculty of Medicine
- Pemetrexed and cyclophospadmide in patients with locally advaced or metastatic breast cancer: A phase I study2003 | First Faculty of Medicine
- New options of expensive pneumo-oncological therapy for advanced non-small-cell lung carcinoma (NSCLC) in the first line based on morphological and molecular genetic diagnosis in the Czech Republic2012 | First Faculty of Medicine, Faculty of Medicine in Pilsen, Central Library of Charles University
- Thyroid transcription factor 1 expression is associated with outcome of patients with non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy2017 | Faculty of Medicine in Hradec Králové, Faculty of Medicine in Pilsen
- Pleural mesothelioma2023 | Third Faculty of Medicine
- Comparison of Chemotherapeutic Regimens Frequently Used in Metastatic Non-squamous NSCLC Treatment2021 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine, Faculty of Medicine in Pilsen, Third Faculty of Medicine
- Can Previous Chemotherapy Affect the Outcome of Nivolumab Treatment in Non-small Cell Lung Cancer?2022 | Faculty of Medicine in Hradec Králové, Faculty of Medicine in Pilsen, Central Library of Charles University
- Phase I study of pemetrexed (ALIMTA) and cyclophosphamide inpatients with locally advanced or metastatic breast cancerPublication without faculty affiliation
- A phase 1 study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer2006 | First Faculty of Medicine
- A phase 1 study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer2006 | Faculty of Physical Education and Sport
- Monitoring of the expensive pneumooncological tratment of the advanced non-small cell lung cancer (NSCLC) in the 1st line in the TULUNG registry in the Czech Republic2012 | First Faculty of Medicine, Third Faculty of Medicine
- The TULUNG clinical registry2012 | First Faculty of Medicine
- Clinical registry Tulung2012 | Publication without faculty affiliation
- Erlotinib in the first line treatment of the metastatic non-small cell lung cancer2018 | Third Faculty of Medicine
- Individualized therapy in non small cell lung Cancer (NSCLC)2011 | First Faculty of Medicine, Faculty of Medicine in Pilsen
